



INTERIM REPORT
1 JULY - 30 SEPTEMBER 2018

VICORE PHARMA HOLDING AB (PUBL)

SUMMARY OF THE PERIOD

“The rights issue in September was oversubscribed by 33% and the company received SEK 82.4 million before issue costs”

Definitions: Vicore Pharma Holding AB (“Vicore” or “the Company”); Vicore Pharma AB (“Vicore Pharma”); INIM Pharma AB (“INIM”).

IMPORTANT EVENTS DURING THE THIRD QUARTER

- In July, Vicore announced it had entered into an agreement to acquire INIM, a Swedish biopharmaceutical company developing a new local treatment for severe rare interstitial lung diseases. Before the acquisition, HealthCap VII L.P. owned 85% of INIM and, following the transaction, became the largest shareholder in Vicore Pharma Holding AB with 30.4% of the shares
- In August, an extraordinary general meeting was held in Vicore and passed resolutions on the following:
 - Issue in kind regarding the acquisition of INIM
 - Dividend of the majority of the holding in I-Tech AB to Vicore shareholders
 - Pre-emptive rights issue in Vicore
 - Long-term incentive programs for certain senior leaders and board members
- Election of two new board members in Vicore: Hans Schikan and Jacob Gunterberg
- In August, Vicore announced that Carl-Johan Dalsgaard was appointed new CEO as of September 1, 2018
- In September, Vicore announced that the clinical program VP01 (C21) was expanded in order to increase the likelihood of showing signals of functional effect and successfully advance C21 in its clinical development
- In September, Vicore Pharma strengthened its team with two key hires: Rohit Batta as CMO and Göran Tornling as Senior Adviser

IMPORTANT EVENTS AFTER THE PERIOD

- In October, Vicore announced that the rights issue completed in September was oversubscribed by 33% and that 99.4% of the subscription rights had been exercised
- In October, Göran Wessman announced that, due to health reasons, he wished to resign from the Board of Directors and instead join Vicore’s nomination committee
- On November 8, the Board decided to act for the Company’s shares to be admitted for trading on Nasdaq Stockholm’s main list in 2019

FINANCIAL SUMMARY (GROUP)

KSEK	July-Sept 2018	July-Sept 2017	Jan-Sept 2018	Jan-Sept 2017	Year 2017
Income	785	929	2 467	2 680	3 674
Operating profit/loss	-6 405	-1 685	-16 245	-6 512	-12 793
Profit/loss after financial items	-6 667	-1 687	2 705	-6 573	-12 855
Earnings per share, SEK	-0.27	-0.11	0.11	-0.41	-0.81
Equity as of end of period	144 623	119 557	144 623	119 557	112 969
Cash flow from operating activities	700	-1 718	8 375	-8 409	-7 703
Cash flow from investing activities	14 845	-5 772	1 253	-13 665	-22 780
Cash flow from financing activities	-1 438	0	-1 438	50 542	50 236
Cash and cash equivalents as of end of period	32 209	32 734	32 209	32 734	24 019

CEO COMMENTS

Dear shareholder,

On July 3, the foundation of the new Vicore was created with the acquisition of INIM and the related decision to distribute the majority of I-Tech shares to the company's shareholders. Vicore gained a clear focus on lung diseases and a broader portfolio focused on idiopathic pulmonary fibrosis (IPF) and other rare lung diseases. The company also gained an active and experienced owner in HealthCap, one of Europe's leading life science investors.

At the Extraordinary General Meeting on August 13, the acquisition and the distribution of shares were approved. At the meeting, two new board members were elected: Hans Schikan, with long experience from the biotech industry, and Jacob Gunterberg from HealthCap. Furthermore, it was also resolved to launch the rights issue that was then successfully completed on October 3, after the end of the quarter. The subscription rights were exercised to 99.4%, the issue was oversubscribed by 33% and the company received SEK 82.4 million before issue costs.

With these decisions made, I was appointed CEO of Vicore from September 1. I was involved in the acquisition deal and saw significant potential in bringing together Vicore and INIM to concentrate efforts within lung disease. Vicore Pharma's data on C21 and its biological mechanism of action could be complemented in an excellent way by INIM's development project in interstitial lung diseases.

At the beginning of September, following a strategic review, we decided to extend Vicore's clinical program VP01 for C21 so that the planned Phase IIa study with C21 for the treatment of IPF could also include data on lung function, i.e. data on both safety and efficacy. Our review included the results of the previously conducted longer preclinical safety study which showed that we have the opportunity to increase exposure to determine higher doses of C21 in humans before selecting the optimal dosing for the clinical study in IPF. We plan to initiate the extended program in January 2019 and then start the Phase IIa study six months later.



In September, Vicore Pharma's organisation was strengthened with two key individuals, both possessing the form of specialist expertise and experience we need to build value in our core focus area of severe, rare lung diseases. They are: Dr. Rohit Batta, who has lengthy experience both as a physician and as a leader of medical and clinical development teams in "rare diseases", most recently in his role as Senior Director of Cell and Gene Therapy at GlaxoSmithKline (GSK); and Dr. Göran Tornling, with nearly 40 years of experience as a specialist physician in pulmonary medicine. Göran was previously Executive Director, Clinical Science and Strategy (Respiratory) at AstraZeneca. In that role, he was responsible for designing studies in IPF. Both Rohit and Göran will be members of Vicore's management team and they will contribute significant value as we now build a world-class medical team for the continued clinical development work ahead of us.

When I took on the role as CEO at Vicore, I saw a good opportunity to create an internationally leading company in severe and rare lung diseases. Now, after two months on the job, I am even more convinced of this.

Carl-Johan Dalsgaard

BUSINESS AND FOCUS AREAS

Vicore Pharma is a Swedish research and development company focused on interstitial lung diseases and associated indications. The Company has been developing the compound C21, with which a Phase IIa study in idiopathic pulmonary disease (IPF) will be initiated in 2019.

In August, INIM was acquired, which means that the company has gained VP02, a pharmaceutical project focused on IPF and additional interstitial lung diseases. The acquisition results in a broadening of activities within the focus area of interstitial lung diseases. In addition, the acquisition of INIM means that the Company gains additional expertise in drug development and interstitial lung disease.

Vicore Pharma's operations are firmly planted in more than ten years of research and development of a new type of drug that stimulates the AT2 receptor (so-called AT2 agonists) and is active within the Renin-Angiotensin System (RAS). The drug candidate C21 is the first small-molecule compound in its class. As such, it has attracted significant research interest and has been the subject of more than 100 scientific articles, mainly about effects in preclinical disease models.

Based on the extensive research that has taken place in relation to C21, Vicore Pharma has chosen to focus the clinical development of the drug candidate on IPF and related indications.


VISION

Vicore Pharma's vision is to cure serious fibrotic lung diseases.

GOAL

Vicore Pharma's goal is to establish the Company as a leading player in severe and rare interstitial lung disease and related indications. Through clinical studies, Vicore Pharma will document the therapeutic properties of VP01 (C21) and VP02 (IMiD-technology) in IPF and other indications. Through strong clinical data, Vicore Pharma will build significant value in the Company and thereby create the prerequisites for future financing and commercial collaborations. The Company's long term goal is to obtain regulatory approval and launch medicines to help patients suffering from severe fibrotic lung diseases.

“ With an expanded product portfolio in an area where there is significant unmet medical need, we are building significant value for Vicore Pharma ”



* Refers to preparations for inclusion of patients in a Phase II / III study

OTHER INFORMATION

PERSONNEL

As of 30 September, the group had five employees. In addition, the Company hires consultants for specialist tasks.

TRANSACTIONS WITH CLOSELY RELATED PARTIES

No transactions have been carried out with closely related parties during the period.

THE SHARE

Vicore's shares were listed on Nasdaq First North on December 10, 2015, with the ticker VICO and ISIN SE0007577895. As of 30 September, the total number of shares amounted to 24 720 006 and the market capitalization was approximately SEK 465 million. The company's shares are issued in one class of and each share carries one vote at the General Meeting.

INCENTIVE PROGRAM

On January 8, 2016, Vicore Pharma Holding issued 570 000 warrants to key employees and key researchers. The increase in the Company's share capital in full exercise of the warrants will amount to SEK 285 000, which corresponds to a dilution of 2.3 percent of the total number of shares and of the total number of votes in the company.

The incentive program to issue 150 000 warrants that was resolved at the Annual General Meeting on June 13 has not been exercised since a new incentive program was resolved at the Extraordinary General Meeting on August 13. Consequently, it will be cancelled with the Swedish Companies Registration Office (Bolagsverket).

At the Extraordinary General Meeting on August 13, it was resolved to implement two new incentive programs: a maximum of 2,000,000 warrants to senior leaders and key persons ("Co-worker LTIP 2018"); and a maximum of 475,000 share awards to board members ("Board LTIP 2018"). The increase in the Company's share capital in full utilization of both incentive programs amounts to a maximum of approximately SEK 1 237 500, corresponding to a dilution of 9.2 percent of the total number of shares.

During the period, 300,000 options were granted to senior managers and key employees in accordance with Co-worker LTIP 2018.

SHARE ISSUES

At the Extraordinary General Meeting on August 13, an issue in kind was resolved regarding the acquisition of INIM. The company's share capital increased by SEK 4 425 751 upon issuance of 8 851 502 shares. At the same general meeting, it was resolved to do a rights issue of a maximum of 8 240 002 shares. After the period, the Company announced that the rights issue was oversubscribed by 33% and that 99.4% of the warrants were exercised. This means that the share capital increased by approximately SEK 4 120 001 and that the Company through the rights issue received SEK 82.4 million before issue costs. Following the rights issue, the number of shares in the Company amounts to 32 960 008.

AUDITOR

After the period, Andreas Mast from Ernst & Young was appointed as new auditor of the company. Andreas Mast replaces Stefan Kylebäck.

CERTIFIED ADVISER

The company has engaged Erik Penser Bank as a Certified Adviser at Nasdaq First North.

I-TECH, FINANCIAL ASSET

At the Extraordinary General Meeting on 13 August, it was resolved to distribute 1 983 563 shares in I-Tech AB to shareholders in Vicore. After the dividend has been registered with Euroclear, Vicore holds 91 829 shares in I-Tech. The distribution of shares in I-Tech is based on a refinement of Vicore's drug development business through the acquisition of INIM, which also resulted in HealthCap entering as the largest shareholder in Vicore.

RISK FACTORS

Vicore Pharma Holding AB (publ) leads and supports activities and operations in the subsidiary Vicore Pharma. Vicore Pharma is a development company conducting clinical studies. These involve an inherent level of risk. There is a risk that the company does not reach its financial goals. This scenario could lead to negative financial implications for Vicore in the future.

AUDIT REVIEW

The interim report has not been subject to audit.

LARGEST SHAREHOLDERS

as of 29 september

Shareholder	No. of shares	%
HealthCap VII L.P.	7 523 777	30.4%
Protem Wessman AB incl. private	2 525 137	10.2%
Swedbank Robur	1 570 000	6.3%
HBM Healthcare Investments (Cayman) Ltd	1 200 000	4.9%
Kjell Stenberg	1 148 478	4.6%
Pomona-gruppen AB	805 830	3.2%
Unionen	600 000	2.4%
Eriksam Invest AB incl. private	591 285	2.4%
Carl-Johan Dalsgaard	477 981	1.9%
Mikael Lönn	448 859	1.8%
Other (approx. 1 650 shareholders)	8 306 640	33%
Total number of shares	24 720 006	100%

FINANCIAL INFORMATION

OPERATING PROFIT/LOSS

Operating profit for the third quarter amounted to -6 405 KSEK (-1 685). The increase compared with the previous year is linked to increased salary costs. During the period, new recruitments have been made to operational activities and the number of board members has increased. During the third quarter, there was also a one-off cost consisting of final salary and severance pay to the former CEO, which was booked as a salary expense for the period and accrued salary (liability). Operating profit for the period was also negatively affected by depreciations of intangible assets. These consist of a depreciation that has started of the main patent for VP01 (C21) and a depreciation of goodwill after the acquisition of INIM. Since the acquisition is of a strategic nature, the depreciation period for goodwill is 10 years. This means a profit effect of approximately -0.4 MSEK per month, or approximately -5.1 MSEK per year.

Profit after financial items amounted to -6 667 KSEK (-1 687). Financial expenses during the period consisted of interest expenses for bridge loan taken with Erik Penser Bank in June 2018. Earnings per share before and after dilution amounted to SEK -0.27 and SEK -0.24 respectively.

CASH FLOW AND INVESTMENTS

Cash flow from operating activities for the third quarter amounted to 700 KSEK (-1 718). The increase compared with the previous year is linked to an increase in accounts payable and short-term liabilities. Cash flow from investing activities amounted to 14 845 KSEK (-5 772). Development costs are capitalised directly and are not accounted for in the income statement. Acquisition of capitalised expenses for development work amounted to -5 228 KSEK (-5 525). The increase compared with the previous year is in its entirety related to the completed acquisition of INIM,

which consisted of 20 MSEK at the time of acquisition. Cash flow from financing activities amounted to -1 438 KSEK (0).

EQUITY

Total equity amounted to 144 623 KSEK (119 557) as of 30 September, equivalent to SEK 5.85 (7.53) per share. The company's liquid assets amounted to 32 209 KSEK (32 734) at the balance sheet date, which is comparable to 18 102 KSEK at the end of the previous quarter. The increase in cash and cash equivalents during the quarter is in its entirety related to the completed acquisition of INIM, which included 20 MSEK at the time of acquisition. The accounting effects of the acquisition of INIM mean that assets increased by 70.8 MSEK, which consists of goodwill of 50.8 MSEK and cash and cash equivalents of 20 MSEK, and equity rose by 70.8 MSEK.

At the extraordinary general meeting on August 13, it was resolved to distribute 1 983 563 shares in I-Tech AB to Vicore shareholders, which means a reduction of the Company's financial assets of approximately 40.7 MSEK and a reduction in equity by approximately 40.7 MSEK. The company's equity ratio at the end of the period was 84.0% (96.9%). The balance sheet total at the end of the period amounted to 172 112 KSEK (123 430).

ACCOUNTING

The interim report has been prepared in accordance with K3.

UPCOMING FINANCIAL REPORTS

February 22, 2019	Year-end report
April 12, 2019	Annual Report
May 15, 2019	Interim report, quarter 1

Financial reports are available on the company's website www.vicorepharma.com from the day of publication.

FINANCIAL SUMMARY (GROUP)

KSEK	July-Sept 2018	July-Sept 2017	Jan-Sept 2018	Jan-Sept 2017	Year 2017
Income	785	929	2 467	2 680	3 674
Operating profit/loss	-6 405	-1 685	-16 245	-6 512	-12 793
Profit/loss after financial items	-6 667	-1 687	2 705	-6 573	-12 855
Earnings per share, SEK	-0.27	-0.11	0.11	-0.41	-0.81
Equity as of end of period	144 623	119 557	144 623	119 557	112 969
Cash flow from operating activities	700	-1 718	8 375	-8 409	-7 703
Cash flow from investment activities	14 845	-5 772	1 253	-13 665	-22 780
Cash flow from financing activities	-1 438	0	-1 438	50 542	50 236
Cash and cash equivalents as of end of period	32 209	32 734	32 209	32 734	24 019

FINANCIAL REPORTS GROUP

SUMMARY INCOME STATEMENT GROUP

<i>KSEK</i>	July-Sept 2018	July-Sept 2017	Jan-Sept 2018	Jan-Sept 2017	Jan-Dec 2017
Operating income etc					
Net turnover	109	230	472	725	932
Own work capitalized	676	673	1 980	1 908	2 645
Other operating income	0	26	15	47	97
	785	929	2 467	2 680	3 674
Operating expenses					
Other external expenses	-1 816	-1 067	-6 155	-4 300	-5 431
Personnel costs	-4 449	-1 546	-8 201	-4 266	-6 209
Depreciation and write-down of tangible assets	-925	-1	-1 662	-5	-7
Depreciation and write-down of intangible assets	0	0	0	-621	-4 410
Share of result in associated companies	0	0	-2 694	0	-410
	-7 190	-2 614	-18 712	-9 192	-16 467
Operating profit/loss	-6 405	-1 685	-16 245	-6 512	-12 793
Profit/loss from financial items					
Share of result in associated companies	0	0	19 267	0	0
Interest income	0	0	0	0	0
Interest expense	-262	-2	-317	-61	-62
	-262	-2	18 950	-61	-62
Profit/loss after financial items	-6 667	-1 687	2 705	-6 573	-12 855
Tax	0	0	0	0	0
Profit/loss for the period	-6 667	-1 687	2 705	-6 573	-12 855

SUMMARY BALANCE SHEET GROUP

<i>KSEK</i>	30-Sep 2018	30-Sep 2017	31-Dec 2017
Assets			
Fixed assets			
Intangible assets	136 942	69 248	72 029
Tangible assets	23	30	28
Financial assets	1 883	20 610	22 745
Total fixed assets	138 848	89 888	94 802
Current assets			
Current receivables			
Customer receivables	91	185	206
Other receivables	610	438	337
Prepaid expenses and accrued income	354	185	164
Cash and bank	32 209	32 734	24 019
Total current assets	33 264	33 542	24 726
Total assets	172 112	123 430	119 528
EQUITY AND LIABILITIES			
Equity, group			
Restricted equity	43 874	20 331	39 448
Non-restricted equity	100 749	99 226	73 521
Total equity, group company	144 623	119 557	112 969
Provisions			
Deferred tax liability	1 978	1 978	1 978
Current liabilities			
Trade payables	5 488	715	2 780
Current tax liability	237	97	143
Other liabilities	15 520	329	250
Accrued expenses	4 266	754	1 408
	25 511	1 895	4 581
TOTAL EQUITY AND LIABILITIES	172 112	123 430	119 528

SUMMARY CASH-FLOW GROUP

KSEK	2018-07-01 2018-09-30	2017-07-01 2017-09-30	2018-01-01 2018-09-30	2017-01-01 2017-09-30	2017-01-01 2017-12-31
Operating activities					
Operating profit/loss	-6 406	-1 685	-16 246	-6 512	-8 594
Adjustments for non-cash items, etc.	925	2	4 356	626	628
Interest received etc	0	0	0	0	0
Interest paid	-260	-2	-315	-61	-62
Income tax paid	31	50	94	50	57
Cash flow from operating activities before changes in working capital	-5 710	-1 635	-12 111	-5 897	-7 971
Cash flow from changes in working capital					
Decrease(+)/increase(-) in accounts receivable	102	-69	115	-63	-84
Decrease(+)/increase(-) in receivables	164	-118	-464	-212	-90
Decrease(-)/increase(+) in accounts payable	3 304	196	2 708	-1 469	596
Decrease(-)/increase(+) in current liabilities	2 840	-92	18 127	-768	-154
Cash flow from operating activities	700	-1 718	8 375	-8 409	-7 703
Investing activities					
Acquisition of capitalised expenditure for research etc.	-5 288	-5 525	-15 652	-12 900	-19 116
Acquisition of concessions, patents, licences etc.	-125	-247	-125	-731	-1 085
Acquisition of equipment, tools, fixtures and fittings	0	0	0	-34	-34
Effect on acquisition of subsidiaries	20 258	0	20 258	0	0
Sale of long-terms valuable document	0	0	-3 228	0	-2 545
Dividends of long-terms valuable document	0	0	0	0	0
Amortisation payments during the year from group companies	0	0	0	0	0
Loans granted during the year to group companies	0	0	0	0	0
Cash flow from investing activities	14 845	-5 772	1 253	-13 665	-22 780
Financing activities					
New issue for the year	0	0	0	50 542	50 236
Issue costs	-1 438	0	-1 438	0	0
Cash flow from financing activities	-1 438	0	-1 438	50 542	50 236
Change in cash and cash equivalents	14 107	-7 490	8 190	28 468	19 753
Cash and cash equivalents at beginning of year	18 102	40 224	24 019	4 266	4 266
Cash and cash equivalents at end of period	32 209	32 734	32 209	32 734	24 019

FINANCIAL REPORTS PARENT COMPANY

SUMMARY INCOME STATEMENT PARENT COMPANY

<i>KSEK</i>	July-Sept 2018	July-Sept 2017	Jan-Sept 2018	Jan-Sept 2017	Jan-Dec 2017
Operating income etc					
Net turnover	648	737	2 076	2 226	2 974
Other operating income	53	0	68	3	8
	701	737	2 144	2 229	2 982
Operating expenses					
Other external expenses	-1 044	-694	-3 920	-3 172	-3 879
Personnel costs	-3 802	-975	-5 841	-2 505	-3 530
Depreciation and write-down of tangible and intangible assets	-2	-2	-5	-5	-7
	-4 848	-1 671	-9 766	-5 682	-7 416
Operating profit/loss	-4 147	-934	-7 622	-3 453	-4 434
Profit/loss from financial items					
Profit/loss from financial items	393	111	952	414	616
Other interest income from group companies	0	0	0	0	0
Interest expense and similar profit/loss items	-261	-1	-314	-58	-58
	132	110	638	356	558
Profit/loss after financial items	-4 015	-824	-6 984	-3 097	-3 876
Tax	0	0	0	0	0
Profit loss for the period	-4 015	-824	-6 984	-3 097	-3 876

SUMMARY BALANCE SHEET PARENT COMPANY

<i>KSEK</i>	30-Sep 2018	30-Sep 2017	31-Dec 2017
Assets			
Fixed assets			
Intangible assets	0	0	0
Tangible assets	23	30	28
Financial assets	145 020	80 624	83 169
Receivables from group companies	40 289	14 661	19 930
Total fixed assets	185 332	95 315	103 127
Current assets			
Current receivables			
Trade receivables	110	164	206
Receivables from Vicore Pharma AB	664	393	0
Other receivables INIM AB	239	0	0
Other receivables	306	1	1
Prepaid expenses and accrued income	310	174	73
Cash and bank	9 186	31 076	22 902
Total current assets	10 815	31 808	23 182
TOTAL ASSETS	196 147	127 123	126 309
EQUITY AND LIABILITIES			
Equity			
Restricted equity	12 360	7 934	7 934
Non-restricted equity	162 387	117 696	116 611
Total equity	174 747	125 630	124 545
Long-term liabilities			
Liabilities to group companies	400	400	400
Current liabilities			
Trade payables	1 377	179	404
Current tax liability	117	49	69
Other liabilities	15 399	242	143
Accrued expenses and deferred income	4 107	623	748
	21 000	1 093	1 364
TOTAL EQUITY AND LIABILITIES	196 147	127 123	126 309

SUMMARY CASH-FLOW PARENT COMPANY

KSEK	2018-07-01 2018-09-30	2017-07-01 2017-09-30	2018-01-01 2018-09-30	2017-01-01 2017-09-30	2017-01-01 2017-12-31
Operating activities					
Operating profit/loss	-4 148	-935	-7 624	-3 453	-4 434
Adjustments for non-cash items, etc.	1	1	5	5	7
Interest received etc	393	112	952	414	616
Interest paid	-261	0	-313	-58	-58
Income tax paid	18	39	48	-15	-5
Cash flow from operating activities before changes in working capital	-3 997	-783	-6 932	-3 107	-3 874
Cash flow from changes in working capital					
Decrease(+)/increase(-) in accounts receivable	-40	-127	-568	-24	326
Decrease(+)/increase(-) in receivables	-510	201	-781	28	130
Decrease(-)/increase(+) in accounts payable	1 078	3	973	-139	86
Decrease(-)/increase(+) in current liabilities	2 990	-11	18 615	-184	-158
Cash flow from operating activities	-479	-717	11 307	-3 426	-3 490
Investing activities					
Acquisition of capitalised expenditure for research etc.	0	0	0	0	0
Acquisition of concessions, patents, licences etc.	0	0	0	0	0
Acquisition of equipment, tools, fixtures and fittings	0	0	0	-34	-34
Sale of long-terms valuable document	0	0	-3 228	0	-2 545
Acquisition of group companies	0	0	0	-31 400	-31 400
Amortisation payments during the year from group companies	0	-5 846	0	12 275	7 006
Loans granted during the year to group companies	-3 991	0	-20 359	0	0
Cash flow from investing activities	-3 991	-5 846	-23 587	-19 159	-26 973
Financing activities					
New issue for the year	0	0	0	50 542	50 236
Issue costs	-1 438	0	-1 438	0	0
Cash flow from financing activities	-1 438	0	-1 438	50 542	50 236
Change in cash and cash equivalents	-5 908	-6 563	-13 718	27 957	19 773
Cash and cash equivalents at beginning of year	15 092	37 639	22 902	3 119	3 119
Cash and cash equivalents at end of period	9 184	31 076	9 184	31 076	22 902

The Board of Directors and the CEO certify that the interim report gives a true and fair view of the Company's operations.

Mölndal, 8 November 2018

Leif Darner, Chairman of the Board
Kjell Stenberg, Board Member
Peter Ström, Board Member
Sara Marcus, Board Member
Maarten Kraan, Board Member
Jacob Gunterberg, Board Member
Hans Schikan, Board Member
Carl-Johan Dalsgaard, Chief Executive Officer

ADDRESS

Vicore Pharma Holding AB
c/o BioVentureHub
Pepparedsleden 1
431 83 Mölndal
SWEDEN
Tel: +46 (0)31-788 05 60
Swedish corporate reg. no.:
556680-3804
www.vicorepharma.com

CONTACT

Hans Jeppsson, CFO
Tel: +46 70 553 14 65
hans.jeppsson@vicorepharma.com
Leif Darner, Chairman of The Board
Tel: +46 70 579 04 62
leif.darner@vicorepharma.com